CRL

Charles River Laboratories International, Inc.NYSEHealthcare

$173.89-0.58%ClosedMarket Cap: $8.56B

As of 2026-04-06

Valuation

P/E (TTM)

—

PEG

—

P/B

2.70

P/S

2.13

EV/EBITDA

14.24

DCF Value

$115.41

FCF Yield

6.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

32.9%

Operating Margin

10.7%

Net Margin

-3.6%

ROE

-4.4%

ROA

-3.6%

ROIC

7.1%

Income Statement

Period	Revenue	Gross Margin	Operating Income	Net Income	EPS	Dividend
Q4 2025	$994.2M	31.0%	$120.2M	$-276.6M	$-5.62	—
FY 2025	$4.02B	30.5%	$507.8M	$-144.3M	$-2.91	—
Q3 2025	$1.00B	33.7%	$133.8M	$54.4M	$1.10	—
Q2 2025	$1.03B	34.6%	$100.1M	$52.3M	$1.06	—
Q1 2025	$984.2M	32.3%	$74.7M	$25.5M	$0.50	—
Q4 2024	$1.00B	28.4%	$-167.7M	$-215.7M	$-4.22	—
FY 2024	$4.05B	32.9%	$227.3M	$10.3M	$0.20	—
Q3 2024	$1.01B	34.6%	$117.4M	$68.7M	$1.33	—
Q2 2024	$1.03B	34.5%	$151.7M	$90.0M	$1.74	—
Q1 2024	$1.01B	34.1%	$126.0M	$67.3M	$1.30	—
Q4 2023	$1.01B	35.9%	$132.9M	$187.1M	$3.62	—
FY 2023	$4.13B	36.4%	$617.3M	$474.6M	$9.22	—